Ratings Teleflex Incorporated

Equities

TFX

US8793691069

Market Closed - Nyse Other stock markets 04:00:01 2024-04-29 pm EDT			5-day change	1st Jan Change
208.5 ^USD	+0.86%		+0.58%	-16.39%

Apr. 15	Truist Securities Adjusts Teleflex Price Target to $240 From $265, Hold Rating Kept	MT
Apr. 02	Teleflex Incorporated Introduces the UroLift? 2 System with Advanced Tissue Control, A Revolutionary Unified Platform Designed to Treat All Prostate Types	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
According to Refinitiv, the company's ESG score for its industry is good.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company returns high margins, thereby supporting business profitability.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The firm trades with high earnings multiples: 27.44 times its 2024 earnings per share.
With an enterprise value anticipated at 3.35 times the sales for the current fiscal year, the company turns out to be overvalued.
The company is not the most generous with respect to shareholders' compensation.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
TELEFLEX INCORPORATED	-16.39%	9.82B	B
ABBOTT LABORATORIES	-2.54%	186B	C+
MEDTRONIC PLC	-1.85%	107B	C
BECTON, DICKINSON AND COMPANY	-4.26%	67.44B	A
DEXCOM, INC.	+1.39%	50.03B	B-
CENCORA, INC.	+16.82%	47.81B	B-
HOYA CORPORATION	+4.79%	41.03B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+3.49%	26.85B	B
WEST PHARMACEUTICAL SERVICES, INC.	+0.65%	25.82B	A-
TERUMO CORPORATION	+16.55%	24.74B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes